4/15/2026
Spondyloarthritis (including ankylosing spondylitis) may be closely linked to changes in the gut—particularly involving the intestinal lining, microbiome, and local immune system—according to a recent narrative review published in Autoimmunity Reviews. Beyond summarizing evidence for this gut–joint connection, the authors emphasize a major limitation in the field: current animal and cell-based models do not adequately capture the complexity of the human gut. The authors say that emerging bioengineered systems, such as organoids and gut-on-a-chip platforms, may be essential for advancing both understanding and treatment of the disease.
The review synthesizes existing research rather than presenting new experimental data. The authors draw on studies of the gut microbiome, intestinal barrier function, immune signaling pathways—particularly IL-23/IL-17—and emerging laboratory models such as organoids and microfluidic systems. Their aim is to integrate current knowledge of intestinal involvement in spondyloarthritis and evaluate how newer bioengineered approaches could improve future research.
A central concept is the “gut–joint axis,” in which changes in gut bacteria, intestinal permeability, and mucosal immune activity may contribute to inflammation beyond the gut itself. Across studies, patients with spondyloarthritis often show altered gut microbiota (dysbiosis), subtle impairment of the intestinal barrier, and immune activation in the gut lining. These features overlap with inflammatory pathways involved in joint disease, particularly IL-23 and IL-17 signaling. The authors suggest that IBS-like symptoms in these patients may not represent a separate condition, but instead reflect the same underlying gut–immune dysfunction.
However, most evidence to date is associative rather than causal, and IBS-like symptoms are still not well understood at a biological level. Findings across microbiome and permeability studies are sometimes inconsistent due to differences in methods and study design. Much of the mechanistic understanding is also inferred from inflammatory bowel disease or animal models rather than directly demonstrated in spondyloarthritis. In addition, while organoid and gut-on-a-chip systems are promising, they remain experimental and are not yet validated for clinical use.
Overall, the review highlights the gut as a key site of immune activity in spondyloarthritis and underscores a critical gap in current research tools. The authors argue that more advanced human-relevant models may be necessary to translate biological insights into better, more targeted therapies.
References:
Input your search keywords and press Enter.
